- Home
- ACRS vs ASRT Comparison
ACRS vs ASRT Comparison
Compare ACRS & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- ASRT
- Stock Information
- Founded
- ACRS 2012
- ASRT 1995
- Country
- ACRS United States
- ASRT United States
- Employees
- ACRS N/A
- ASRT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ACRS Health Care
- ASRT Health Care
- Exchange
- ACRS Nasdaq
- ASRT Nasdaq
- Market Cap
- ACRS 165.7M
- ASRT 57.9M
- IPO Year
- ACRS 2015
- ASRT 1997
- Fundamental
- Price
- ACRS $1.59
- ASRT $0.69
- Analyst Decision
- ACRS Strong Buy
- ASRT Strong Buy
- Analyst Count
- ACRS 9
- ASRT 2
- Target Price
- ACRS $9.25
- ASRT $3.25
- AVG Volume (30 Days)
- ACRS 1.3M
- ASRT 259.0K
- Earning Date
- ACRS 08-06-2025
- ASRT 08-06-2025
- Dividend Yield
- ACRS N/A
- ASRT N/A
- EPS Growth
- ACRS N/A
- ASRT N/A
- EPS
- ACRS N/A
- ASRT N/A
- Revenue
- ACRS $17,777,000.00
- ASRT $119,001,000.00
- Revenue This Year
- ACRS N/A
- ASRT N/A
- Revenue Next Year
- ACRS $11.77
- ASRT $11.91
- P/E Ratio
- ACRS N/A
- ASRT N/A
- Revenue Growth
- ACRS N/A
- ASRT N/A
- 52 Week Low
- ACRS $1.05
- ASRT $0.51
- 52 Week High
- ACRS $5.17
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- ACRS 59.88
- ASRT 64.38
- Support Level
- ACRS $1.44
- ASRT $0.63
- Resistance Level
- ACRS $1.52
- ASRT $0.67
- Average True Range (ATR)
- ACRS 0.10
- ASRT 0.03
- MACD
- ACRS 0.00
- ASRT 0.01
- Stochastic Oscillator
- ACRS 79.17
- ASRT 86.37
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.